India’s small and mid-sized pharmaceutical manufacturers are raising alarms over new good manufacturing practice (GMP) and bio-equivalence mandates, warning that the regulations could widen the gap between large companies and micro, small, and medium enterprises (MSMEs).
Indian Pharma | 13/10/2025 | By Darshana
PM Narendra Modi lays foundation stone of bulk drug park in Una, HP
Raw materials for medicine manufacturing will be produced in Himachal Pradesh
Indian Pharma | 13/10/2022 | By Sudeep Soparkar | 382
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy